Daniel Goldmeier of Goldmeier Investments assisted in writing this article.
Too Much Risk Too Soon
Israel's Teva Pharmaceutical Industries Ltd. (TEVA) share price sells a notch above its 19 years low. Yet, I do not recommend retail investors buy this stock now. The company has no major catalysts on the horizon. TEVA still has significant though more manageable debt. It remains exposed to legal liabilities related to the opioid crisis and U.S. charges of price-fixing of pharmaceuticals. In my opinion, given the high risk and low reward profile, retail investors have no business